The Syk Inhibitor Entospletinib Abolishes Dermal –Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid

Bullous pemphigoid (BP) is an autoantibody-mediated blistering skin disease characterized by local inflammation and dermal –epidermal separation, with no approved targeted therapy. The Syk tyrosine kinase is critical for various functions of the immune response. Second-generation Syk inhibitors such as entospletinib are currently being tested for hematological malignancies. Our aim was to test the effect of entospleti nib in a fully human model system of BP. Incubating BP serum–treated human frozen skin sections with normal human granulocytes and fresh plasma triggered dermal–epidermal separation that was dependent on complement, NADPH oxidase, and protease activity.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research